NCT04371224View on ClinicalTrials.gov

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

Irinotecan Liposomal Injection [Onivyde]

both arm

DRUG

Capecitabine

NaliCap

DRUG

5-fluorouracil

NAPOLI

DRUG

Leucovorin

NAPOLI

Trial Locations (2)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

110-744

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04371224 - NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter